MDABY Stock News 17.9500 05/06/2014 16:17:27 Meda Ab (MDABY)
Post# of 273382
Posted On: 05/06/2014 5:17:19 PM
Meda Ab (MDABY) 17.9500 $MDABY
Actinic (Solar) Keratosis Therapeutic Pipeline Review 2014 - Includes 14 Company Profiles and 22 Drug Profiles
M2 - Mon Apr 28, 2:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncvwjt/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Scope: - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development: - Biofrontera AG - Galderma S.A. - LEO Pharma A/S - Meda AB - Clinuvel Pharmaceuticals Limited - Quest PharmaTech Inc. - G&E Herbal Biotechnology Co., Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Foamix Ltd. - Telormedix SA - Genextra S.p.a. - Novelix Pharmaceuticals, Inc. - Advancell Drug Profiles: - aminolevulinic acid hydrochloride - SRT-100 - afamelanotide - sotirimod - resiquimod - AK-3012 - DAC-0060 - AD-17137 - LEO-43204 - disitertide - SL-017 - TMX-202 - P-529 - CUV-9900 - ANs-40 - NVX-207 - ANS-401 - ANS-403 - imiquimod - Drug For Actinic Keratosis - DNA Repair Polypeptides - Ingenol Mebutate Analogs for Dermatology and Cancer For more information visit http://www.researchandmarkets.com/research/nc...inic_solar
Valeant Pharmaceuticals Announces Nominations For Board Of Directors
CNW Group - Wed Apr 23, 7:01AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today its nominees to stand for election to the Board of Directors at its annual meeting of shareholders on May 20, 2014. Given Valeant's increased size as a company and its ability to look at a broader set of business development opportunities, three of our Directors, who have full-time jobs looking at healthcare investment opportunities, feel that continued service on the Valeant Board could limit their professional effectiveness, and will not be included in the slate. These directors include Fred Hassan, Partner and Managing Director at Warburg Pincus LLC, G. Mason Morfit, President at ValueAct, LLC, focused on healthcare and technology sectors, and Lloyd M. Segal, Managing Partner at Persistence Capital Partners, LP, which has two active healthcare private equity funds. All other current directors will stand for re-election. The Board did not include Messrs. Hassan, Morfit and Segal on the nominee slate after taking into consideration their preferences and other commitments. Newly selected nominees include Colleen Goggins, former Johnson & Johnson Worldwide Chairman Consumer Group, Executive Committee, and Anders Lonner, former Chief Executive Officer of Meda AB.
Meda announces termination of JV with Valeant
M2 - Tue Apr 08, 6:16AM CDT
Swedish speciality pharmaceutical company Meda AB (STO: MEDAA) announced on Monday that it has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014.
Tech stocks, once highfliers, drop; Nasdaq sinks
By MATTHEW CRAFT - AP - Fri Apr 04, 3:39PM CDT
NEW YORK (AP) — A slump in Internet and other technology stocks pulled the broader market lower Friday, as traders turned on the same companies they flocked to earlier this year. Google, Netflix and other pillars of the Internet economy took a beating.
Meda turns down approach from Mylan
AP - Fri Apr 04, 9:44AM CDT
NEW YORK (AP) — Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses.
Meda AB (publ) Notice of Annual General Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Notice is hereby given that the Annual General Meeting (AGM) of Meda AB (STO:MEDAA), corporate ID 556427-2812, will be held at 5.00 PM on Wednesday, May 7, 2014 at Meda's headquarters at Pipers vag 2A, Solna, Sweden. Registration starts at 4.00 PM.
MEDA: Nomination Committee's Proposal for Composition of the Board
Business Wire - Fri Mar 28, 4:04AM CDT
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Tue Feb 11, 7:48AM CST
Meda AB (STO:MEDAA):
Meda announces organisational changes
M2 - Mon Aug 05, 3:20AM CDT
Specialty pharma company Meda AB (STO:MEDAA.ST) announced today that Jorg-Thomas Dierks, its chief operating officer (COO), will now have expanded responsibilities which will include Meda's US operations.
MEDA posts net profit of SEK400m in H1 2013
M2 - Fri Aug 02, 10:07AM CDT
Speciality pharmaceutical company MEDA AB (STO:MEDAA) today reported interim profit after tax of SEK400m, or SEK1.34 per share, for the period January 2013 to June 2013.
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
Meda AB (publ) AGM bulletin
Business Wire - Tue May 07, 12:31PM CDT
Regulatory News:
MEDA: Interim Report, January-March 2013
Business Wire - Tue May 07, 1:31AM CDT
Regulatory News:
Actinic (Solar) Keratosis Therapeutic Pipeline Review 2014 - Includes 14 Company Profiles and 22 Drug Profiles
M2 - Mon Apr 28, 2:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncvwjt/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Scope: - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development: - Biofrontera AG - Galderma S.A. - LEO Pharma A/S - Meda AB - Clinuvel Pharmaceuticals Limited - Quest PharmaTech Inc. - G&E Herbal Biotechnology Co., Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Foamix Ltd. - Telormedix SA - Genextra S.p.a. - Novelix Pharmaceuticals, Inc. - Advancell Drug Profiles: - aminolevulinic acid hydrochloride - SRT-100 - afamelanotide - sotirimod - resiquimod - AK-3012 - DAC-0060 - AD-17137 - LEO-43204 - disitertide - SL-017 - TMX-202 - P-529 - CUV-9900 - ANs-40 - NVX-207 - ANS-401 - ANS-403 - imiquimod - Drug For Actinic Keratosis - DNA Repair Polypeptides - Ingenol Mebutate Analogs for Dermatology and Cancer For more information visit http://www.researchandmarkets.com/research/nc...inic_solar
Valeant Pharmaceuticals Announces Nominations For Board Of Directors
CNW Group - Wed Apr 23, 7:01AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today its nominees to stand for election to the Board of Directors at its annual meeting of shareholders on May 20, 2014. Given Valeant's increased size as a company and its ability to look at a broader set of business development opportunities, three of our Directors, who have full-time jobs looking at healthcare investment opportunities, feel that continued service on the Valeant Board could limit their professional effectiveness, and will not be included in the slate. These directors include Fred Hassan, Partner and Managing Director at Warburg Pincus LLC, G. Mason Morfit, President at ValueAct, LLC, focused on healthcare and technology sectors, and Lloyd M. Segal, Managing Partner at Persistence Capital Partners, LP, which has two active healthcare private equity funds. All other current directors will stand for re-election. The Board did not include Messrs. Hassan, Morfit and Segal on the nominee slate after taking into consideration their preferences and other commitments. Newly selected nominees include Colleen Goggins, former Johnson & Johnson Worldwide Chairman Consumer Group, Executive Committee, and Anders Lonner, former Chief Executive Officer of Meda AB.
Meda announces termination of JV with Valeant
M2 - Tue Apr 08, 6:16AM CDT
Swedish speciality pharmaceutical company Meda AB (STO: MEDAA) announced on Monday that it has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014.
Tech stocks, once highfliers, drop; Nasdaq sinks
By MATTHEW CRAFT - AP - Fri Apr 04, 3:39PM CDT
NEW YORK (AP) — A slump in Internet and other technology stocks pulled the broader market lower Friday, as traders turned on the same companies they flocked to earlier this year. Google, Netflix and other pillars of the Internet economy took a beating.
Meda turns down approach from Mylan
AP - Fri Apr 04, 9:44AM CDT
NEW YORK (AP) — Swedish drug company Meda has rebuffed an approach from generic drug maker Mylan which was looking to combine the two businesses.
Meda AB (publ) Notice of Annual General Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Notice is hereby given that the Annual General Meeting (AGM) of Meda AB (STO:MEDAA), corporate ID 556427-2812, will be held at 5.00 PM on Wednesday, May 7, 2014 at Meda's headquarters at Pipers vag 2A, Solna, Sweden. Registration starts at 4.00 PM.
MEDA: Nomination Committee's Proposal for Composition of the Board
Business Wire - Fri Mar 28, 4:04AM CDT
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Tue Feb 11, 7:48AM CST
Meda AB (STO:MEDAA):
Meda announces organisational changes
M2 - Mon Aug 05, 3:20AM CDT
Specialty pharma company Meda AB (STO:MEDAA.ST) announced today that Jorg-Thomas Dierks, its chief operating officer (COO), will now have expanded responsibilities which will include Meda's US operations.
MEDA posts net profit of SEK400m in H1 2013
M2 - Fri Aug 02, 10:07AM CDT
Speciality pharmaceutical company MEDA AB (STO:MEDAA) today reported interim profit after tax of SEK400m, or SEK1.34 per share, for the period January 2013 to June 2013.
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
Meda AB (publ) AGM bulletin
Business Wire - Tue May 07, 12:31PM CDT
Regulatory News:
MEDA: Interim Report, January-March 2013
Business Wire - Tue May 07, 1:31AM CDT
Regulatory News:
(0)
(0)